Daniel Molano-FrancoAntonio Viruez‐SotoMario GómezEdgar BeltránMario VillabonÁngela SosaLeidy OrtizEstefania OrozcoAlejandra HurtadoLida Sanchez2026-03-222026-03-22202310.4187/respcare.10839https://doi.org/10.4187/respcare.10839https://andeanlibrary.org/handle/123456789/53267Citaciones: 1High-altitude subjects treated with HFNC for COVID-19 showed a high risk of respiratory failure and progressive hypoxemia when F_IO₂ requirements were > 0.8 after 24 h of treatment. In these subjects, personalized management should include continuous monitoring of individual clinical conditions (such as oxygenation indices, with cutoffs adapted to those corresponding to high-altitude cities).enNasal cannulaMedicineOdds ratioHypoxemiaOxygen therapyARDSProspective cohort studyAnesthesiaInternal medicinearticle